Swain, Mark G.

The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis

Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 2,246

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 757

Cerebral Microglia Recruit Monocytes into the Brain in Response to Tumor Necrosis Factorα Signaling during Peripheral Organ Inflammation

D'Mello, C., Le, T., & Swain, M. G. (2009) · The Journal of Neuroscience

Neuroinflammation and Neurodegeneration MechanismsTryptophan and brain disorders

Cited by 675

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 497

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., et al. (2024) · New England Journal of Medicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 314

Environmental stress–induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat

Meddings, J. B., & Swain, M. G. (2000) · Gastroenterology

Inflammatory Bowel DiseaseGastrointestinal motility and disorders

Cited by 269

Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression

Frolkis, A. D., Vallerand, I. A., Shaheen, A.-A., Lowerison, M. W., Swain, M. G., Barnabe, C., Patten, S. B., & Kaplan, G. G. (2019) · Gut

Inflammatory Bowel DiseaseTryptophan and brain disorders

Cited by 228

Essential Role for Neutrophil Recruitment to the Liver in Concanavalin A-Induced Hepatitis

Bonder, C. S., Ajuebor, M. N., Zbytnuik, L. D., Kubes, P., & Swain, M. G. (2004) · The Journal of Immunology

Drug-Induced Hepatotoxicity and ProtectionLiver physiology and pathology

Cited by 192

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

Jones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 191

Probiotics Improve Inflammation-Associated Sickness Behavior by Altering Communication between the Peripheral Immune System and the Brain

D'Mello, C., Ronaghan, N., Zaheer, R., Dicay, M., Le, T., MacNaughton, W. K., Surrette, M. G., & Swain, M. G. (2015) · Journal of Neuroscience

Tryptophan and brain disordersProbiotics and Fermented Foods

Cited by 187

Open‐label trial of oral nalmefene therapy for the pruritus of cholestasis

Bergasa, N. V., Schmitt, J. M., Talbot, T. L., Alling, D. W., Swain, M. G., Turner, M. L., Jenkins, J. B., & Jones, A. E. (1998) · Hepatology

Dermatology and Skin DiseasesLiver Diseases and Immunity

Cited by 182

Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy

Burak, K. W., Swain, M. G., Santodomino-Garzon, T., Lee, S. S., Urbanski, S. J., Aspinall, A. I., Coffin, C. S., & Myers, R. P. (2013) · Canadian Journal of Gastroenterology

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 167

Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population‐based study†

Myers, R. P., Shaheen, A. A. M., Fong, A., Burak, K. W., Wan, A., Swain, M. G., Hilsden, R. J., Sutherland, L., & Quan, H. (2009) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 135

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 127

The challenges of primary biliary cholangitis: What is new and what needs to be done

Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 114

Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group

Than, N. N., Hodson, J., Schmidt-Martin, D., Taubert, R., Wawman, R. E., Botter, M., Gautam, N., Bock, K., Jones, R., Appanna, G. D., et al. (2019) · JHEP Reports

Liver Diseases and ImmunityIgG4-Related and Inflammatory Diseases

Cited by 101

A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue

Theal, J. J., Toosi, M. N., Girlan, L., Heslegrave, R. J., Huet, P., Burak, K. W., Swain, M., Tomlinson, G. A., & Heathcote, E. J. (2005) · Hepatology

Liver Diseases and ImmunityFibromyalgia and Chronic Fatigue Syndrome Research

Cited by 73

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis

Roberts, S. B., Ismail, M., Kanagalingam, G., Mason, A. L., Swain, M. G., Vincent, C., Yoshida, E. M., Tsien, C., Flemming, J. A., Janssen, H. L. A., et al. (2020) · Hepatology Communications

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 58

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 39

Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 38

Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial

Jones, D., Carbone, M., Invernizzi, P., Little, N., Nevens, F., Swain, M. G., Wiesel, P., & Levy, C. (2023) · Hepatology Communications

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 37